Read by QxMD icon Read

Hematology guideline

Jae Yoon Park, Wei Guo, Mohammed Al-Hijji, Abdallah El Sabbagh, Kebede H Begna, Thomas M Habermann, Thomas E Witzig, Bradley R Lewis, Amir Lerman, Joerg Herrmann
BACKGROUND: Cancer and cardiovascular diseases are the two leading causes of death in industrialized countries. Optimal management of life-threatening presentations of both of their diseases can pose significant challenges. The current study aimed to address the incidence, management, and outcome of acute coronary syndromes (ACS) in patients with active hematological malignancies. METHODS: This retrospective registry-based cohort study included adults with active leukemia or lymphoma who were hospitalized at Mayo Clinic Rochester from 01/01/2004 to 12/31/2014...
October 5, 2018: International Journal of Cardiology
Han-I Wang, Eve Roman, Simon Crouch, Eline Aas, Cathy Burton, Russell Patmore, Alexandra Smith
OBJECTIVES: To use real-world data to develop a flexible generic decision model to predict cost, life expectancy, and quality-adjusted life-years (QALYs) for follicular lymphoma (FL) in the general patient population. METHODS: All patients newly diagnosed with FL in the UK's population-based Haematological Malignancy Research Network ( between 2004 and 2011 were followed until 2015 (N = 740). Treatment pathways, QALYs, and costs were incorporated into a discrete event simulation to reflect patient heterogeneity, including age and disease management...
October 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Tomonori Hirashima, Yoshitaka Tamura, Yuki Han, Shoji Hashimoto, Ayako Tanaka, Takayuki Shiroyama, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Shinobu Akada, Makoto Fujishima, Yoshihisa Kadota, Kazuya Sakata, Akiko Nishitani, Satoru Miyazaki, Takayuki Nagai
BACKGROUND: In our previous study, colorectal cancer (CRC) patients with active Mycobacterium tuberculosis (MTB) tolerated concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy. In this study, we retrospectively confirmed the efficacy and safety of concurrent chemotherapy in a greater number of patients with different types of malignancies. METHODS: We enrolled 30 patients who were treated concurrently with anti-CCT and anti-MTB regimens between January 2006 and February 2016...
October 12, 2018: BMC Cancer
Hermioni L Amonoo, Margot E Barclay, Areej El-Jawahri, Lara N Traeger, Stephanie J Lee, Jeff C Huffman
Positive psychological constructs (e.g., optimism, positive affect) have been independently associated with superior health outcomes across many medical populations. However, there has been little synthesis of the literature examining these associations among patients with hematologic malignancies receiving hematopoietic stem cell transplantation (HSCT). To address this gap, we completed a systematic review, using PRISMA guidelines, of studies examining relationships between positive psychological constructs and health-related outcomes (e...
October 8, 2018: Biology of Blood and Marrow Transplantation
Naoyuki Katayama
In March 2017, considering the recent social trend, the Japanese Association of Medical Sciences (JAMS) officially announced the "JAMS Conflicts of Interest (COI) Management Guideline" and the "JAMS Guidance on Criteria for Qualification to Practice Guideline." In response to this announcement, the Japanese Society of Internal Medicine partially revised and announced the "Common Guideline on the Policy of COI in Medical Research," including the "COI Management to Practice Guideline" and the "Treatment Guideline," for its affiliated societies in September 2017...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Hirokazu Nagai
The Japanese Society of Hematology has revised its clinical practice guidelines for Tumors of Hematopoietic and Lymphoid Tissues, and this version will be published in 2018. In the lymphoma section, the revised 4th edition (2017) of the WHO classification was adopted and reflected in all issues. The descriptions of all clinical questions (CQs) were thoroughly updated according to the latest published studies. The CQs were modified to reflect recent progress in the treatment of follicular, diffuse large B-cell, and Hodgkin lymphomas...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
(no author information available yet)
No abstract text is available yet for this article.
October 2, 2018: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
Jeffrey R Andolina, Michael J Burke, Nobuko Hijiya, Sonali Chaudhury, Kirk R Schultz, Michael E Roth
Chronic myeloid leukemia (CML) is a rare disease in children where pediatric evidence-based guidelines are lacking. We designed an anonymous survey for practicing pediatric oncologists and bone marrow transplant (BMT) physicians to assess their willingness to recommend BMT for a patient with CML based on varied clinical scenarios. Two-hundred seventy-four (274) physicians responded to the survey (13.4% response rate). Nearly all pediatric oncologists and BMT physicians recommended against BMT at time of diagnosis of CML in chronic phase with only 8...
September 26, 2018: Biology of Blood and Marrow Transplantation
Yeh-Chung Chang, Erin Graf, Abby M Green
Curvularia is a saprophytic dematiaceous mold and a rare human pathogen. Here, we report three severely immunocompromised pediatric patients who developed invasive Curvularia infection. Diagnosis was achieved or confirmed in all cases by fungal ribosome sequencing, which hastened species identification and targeted treatment for the patients reported. There are no treatment guidelines for invasive Curvularia infection, though we report three patients who were cured of their infection through a combination of surgical resection and various anti-fungal therapies, indicating a relatively low virulence and good prognosis in comparison to other angioinvasive molds...
September 27, 2018: Journal of the Pediatric Infectious Diseases Society
Michael Leibowitz, Heather Wolfe, Andrea Flynn, Angela Waanders, Caroline Burlingame, Brenna Aumaier, David Friedman, Michele P Lambert
BACKGROUND: Oncology patients are frequent recipients of prophylactic platelet transfusions. Recent studies have demonstrated that lower prophylactic doses of platelets were not associated with a higher incidence of bleeding. At our institution, we found wide variation in platelet dosing due to lack of guidance and support for standardized dosing. STUDY DESIGN AND METHODS: A collaborative process improvement project between oncology, hematology, intensivists, and the transfusion service established guidelines for dosing of prophylactic platelet transfusions in nonbleeding oncology patients: 10 mL/kg or less of apheresis platelets for patients weighing up to 20 kg and 1 unit of apheresis platelets patients weighing 20 kg or more, with our stated goal of standardizing transfusion practice...
September 27, 2018: Transfusion
Branimir Jakšić, Vlatko Pejša, Slobodanka Ostojić-Kolonić, Ika Kardum-Skelin, Sandra Bašić-Kinda, Božena Coha, Velka Gverić-Krečak, Radovan Vrhovac, Ozren Jakšić, Igor Aurer, Jasminka Sinčić-Petričević, Antica Načinović-Duletić, Damir Nemet
Recent developments in the diagnosis and treatment of chronic lymphocytic leukemia (B-CLL) have led to change of approach in clinical practice. New treatments have been approved based on the results of randomized multicenter trials for first line and for salvage therapy, and the results of numerous ongoing clinical trials are permanently providing new answers and further refining of therapeutic strategies. This is paralleled by substantial increase in understanding the disease genetics due to major advances in the next generation sequencing (NGS) technology...
March 2018: Acta Clinica Croatica
Shelly-Anne Li, Paul E Alexander, Tea Reljic, Adam Cuker, Robby Nieuwlaat, Wojtek Wiercioch, Gordon Guyatt, Holger J Schünemann, Benjamin Djulbegovic
OBJECTIVE: It is unclear how guidelines panelists discuss and consider factors (criteria) that are formally and not formally included in the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. To describe the use of decision criteria, we explored how panelists adhered to GRADE criteria, and sought to identify any emerging non-GRADE criteria when panelists used the Evidence to Decision (EtD) framework as part of GRADE application. STUDY DESIGN AND SETTING: We used conventional and summative qualitative analyses to identify themes emerging from face-to-face, panel meeting discussions...
September 22, 2018: Journal of Clinical Epidemiology
Ionela Iacobas, Thuy L Phung, Denise M Adams, Cameron C Trenor, Francine Blei, Douglas S Fishman, Adrienne Hammill, Prakash M Masand, Steven J Fishman
OBJECTIVE: To define the types of hepatic hemangiomas using the updated International Society for the Study of Vascular Anomalies classification and to create a set of guidelines for their diagnostic evaluation and monitoring. STUDY DESIGN: We used a rigorous, transparent consensus protocol defined by an approved methodology, with input from multiple pediatric experts in vascular anomalies from hematology-oncology, surgery, pathology, radiology, and gastroenterology...
September 21, 2018: Journal of Pediatrics
Shang-Yi Lin, Po-Liang Lu, Ban Hock Tan, Arunaloke Chakrabarti, Un-In Wu, Jui-Hsuan Yang, Atul K Patel, Ruo Yu Li, Siriorn P Watcharananan, Zhengyin Liu, Ariya Chindamporn, Ai Ling Tan, Pei-Lun Sun, Li-Yin Hsu, Yee-Chun Chen
BACKGROUND: Current guidelines recommend echinocandins as first-line therapy for candidemia. However, several non-Candida yeasts are non-susceptible to echinocandins (echinocandin non-susceptible yeast, ENSY), including Cryptococcus, Geotrichum, Malassezia, Pseudozyma, Rhodotorula, Saprochaete, Sporobolomyces, and Trichosporon. In laboratories that are not equipped with rapid diagnostic tools, it often takes several days to identify yeasts, and this may lead to inappropriate presumptive use of echinocandins in patients with ENSY fungemia...
September 19, 2018: Mycoses
Yu Wang, Hu Chen, Jing Chen, Mingzhe Han, JianDa Hu, Jiong Hu, He Huang, Yongrong Lai, Daihong Liu, Qifa Liu, Ting Liu, Ming Jiang, Hanyun Ren, Yongping Song, Zimin Sun, Chun Wang, Jianmin Wang, Depei Wu, Kailin Xu, Xi Zhang, Lanping Xu, Kaiyan Liu, Xiaojun Huang
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important curative therapy for patients with leukemia. However, relapse remains the leading cause of death after transplantation. In recent years, substantial progress has been made by Chinese physicians in the field of establishment of novel transplant modality, patient selection, minimal residual disease (MRD) monitoring, and immunological therapies, such as modified donor lymphocyte infusion (DLI) and chimeric antigen receptor T (CART) cells, as well as MRD-directed intervention for relapse...
December 1, 2018: Cancer Letters
Ming Y Lim, Ricardo Yamada, Marcelo Guimaraes, Charles S Greenberg
Background: There is a wide variability in practice patterns on the use of inferior vena cava filters (IVCFs) among institutions, which is likely due to contrasting indication guidelines published by different professional societies. The aim of the present study is to report our healthcare system use of IVCF to: 1) determine practice patterns, 2) determine factors that may predict IVCF retrieval and 3) identify areas for improvement. Methods: A retrospective review of 180 consecutive IVCF placement performed between July 2014 and December 2015 was conducted...
October 2018: Journal of Clinical Medicine Research
Shuvra Neel Baul, Rajib De, Prakas Kumar Mandal, Swagnik Roy, Tuphan Kanti Dolai, Prantar Chakrabarti
Background: Burkholderia cepacia , an aerobic gram-negative bacillus, is a frequent colonizer of fluids used in the hospital ward. It poses little risk of infection to healthy people; however it is a known important opportunistic pathogen causing morbidity and mortality due to its intrinsic resistance to most of the antibiotics in hospitalized patients. Small hospital outbreaks are frequent. B. cepacia may occur as an opportunistic infection in hemato-oncology patients. Here we present an outbreak of Burkholderia cepacia infection in hematology ward of our institute...
2018: Mediterranean Journal of Hematology and Infectious Diseases
Jun-Won Yun, Euna Kwon, Yun-Soon Kim, Seung-Hyun Kim, Ji-Ran You, Hyoung-Chin Kim, Jin-Sung Park, Jeong-Hwan Che, Sang-Koo Lee, Ja-June Jang, Hyeon Hoe Kim, Byeong-Cheol Kang
BACKGROUND: Seed of mature Croton tiglium Linne, also known as Tiglium seed (TS), has been widely used as a natural product due to its several health beneficial properties including anti-tumor and antifungal activities. Despite its ethnomedicinal beneficial properties, toxicological information regarding TS extract, especially its long-term toxicity, is currently limited. Therefore, the objective of the present study was to evaluate acute and subchronic toxicity of TS extract in rats after oral administration following test guidelines of the Organization for Economic Cooperation and Development (OECD)...
September 12, 2018: BMC Complementary and Alternative Medicine
Alexandra Ladouceur, Sasha Bernatsky, Rosalind Ramsey-Goldman, Ann E Clarke
INTRODUCTION: Numerous studies have clearly demonstrated that there is an altered cancer risk profile in patients with systemic lupus erythematous (SLE) versus the general population. This includes a higher risk of certain cancers (e.g. hematologic, lung) and a decreased risk of others (e.g. breast cancer). Several determinants could be behind this altered risk; these include immunosuppressant drugs, viral exposures, genetic factors, and other variables. Area covered: We review what is known regarding specific risk profiles and risk factors for some key cancers in SLE, including hematologic malignancies and lung cancers...
October 2018: Expert Review of Clinical Immunology
Urip Harahap, Hafiza Mitha Agustya, Dira Ummul Azizah, Syari Widia Alfiah
Picria fel-terrae extract has been investigated for its hepatoprotective activity. This current study was conducted to evaluate the subchronic toxic effect of Picria fel-terrae Lour. leaf extract. The subchronic toxicity of ethanol extract of P. fel-terrae leaf was evaluated by OECD (Organization for Economic Cooperation and Development) guidelines. The extract at doses of 125, 250, 500, 1000 mg/kg body weight (BW) were orally administered to the test animals for 90 days. Signs of toxicity and mortality were observed for 90 days and 118 days...
September 4, 2018: Scientia Pharmaceutica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"